Overall Fundamental outlook

Business Operations:

Sector: Healthcare
Industry: Drug Manufacturers - Specialty & Generic

Cipla Limited, together with its subsidiaries, engages in the manufacture, development, sale, and distribution of pharmaceutical products in India, the United States, South Africa, and internationally. The company operates through Pharmaceuticals and New Ventures segments. It offers generic and branded generic medicines, vaccines, active pharmaceutical ingredients, and formulations for various therapeutic areas, such as MI, angina, heart disease, pulmonary disease, kidney failure, Alzheimer's disease, hypertension, arrhythmia, lipid abnormalities and diabetes, obesity, central nervous system, HIV/AIDS, respiratory, asthma, urology, oncology, cardio-metabolism, child health, infectious diseases and critical care, hepatitis, women's health, ophthalmology, and neuro psychiatry. The company is also involved in the consumer healthcare, biosimilars, and specialty businesses. Cipla Limited was incorporated in 1935 and is based in Mumbai, India.

Revenue projections:

Revenue projections for CIPLA
Revenue projections for CIPLA

CIPLA is projected to see lower revenues than in the previous year, a trend that usually concerns investors. Declining revenues often harm a company's profitability, leading investors to exercise caution as they weigh the potential risks of continued financial downturns.

Financial Ratios:

currentRatio 4.24700
forwardPE 22.96884
debtToEquity 1.40400
earningsGrowth 0.30100
revenueGrowth 0.08900
grossMargins 0.66351
operatingMargins 0.19897
trailingEps 65.18000
forwardEps 63.54000

CIPLA's current ratio of 4.247 means the company has enough liquidity to meet its short-term debt obligations. With sufficient cash reserves and current assets, CIPLA can comfortably cover its liabilities, reflecting a strong financial outlook.
CIPLA's Forward PE ratio is favorable, meaning the stock price aligns well with earnings and isn't overvalued. This allows room for growth, making it an attractive investment for those seeking potential upside while ensuring the stock is not overpriced.
Cipla Limited's forward EPS being lower than its trailing EPS indicates that the company's earnings are projected to decrease. This suggests that Cipla Limited may struggle to maintain profitability at previous levels, potentially affecting its financial outlook.

Price projections:

Price projections for CIPLA
Price projections for CIPLA

Price projections for CIPLA have been revised upward over time, signaling increasing optimism about the company's future. This steady increase reflects a positive outlook for CIPLA's growth and market performance.

Insider Transactions:

Insider Transactions for CIPLA
Insider Transactions for CIPLA


CIPLA experienced 2 selling transactions, with market price of 1590.4249877929688.The period under consideration did not see any sell transactions.The trend of more buys than sells at CIPLA's current price levels suggests a possible bullish sentiment. This could indicate that investors are expecting a favorable outlook for the stock, prompting more buying activity.

Recommendation changes over time:

Recommendations trend for CIPLA
Recommendations trend for CIPLA


The recent buy bias from analysts suggests CIPLA is seen as a strong investment, encouraging more investors to consider it. With this favorable sentiment, CIPLA appears to be a reliable option for parking money, offering stability and long-term growth potential in the stock market.